Newsletter Signup | Community
FDA Approves PD-1 Checkpoint Inhibitor Opdivo for Treatment of Bladder Cancer
Dr. Michael O’Donnell, MD, Director of Urologic Oncology University of Iowa answers questions about bladder cancer.
Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer
Study reports that ~ 60% of patients with advanced bladder cancer respond to Votrient/Taxol chemotherapy
Michael O’Donnell, MD, University of Iowa answers questions about what causes bladder cancer.
IDO inhibitor epacadostat and the anti-PD-1 drug Keytruda (pembrolizumab) promising in bladder cancer.
Vicinium promising for treatment of early stage and superficial bladder cancers.